Furthermore, Michl's team revealed claudin-4 overexpression in pancreatic cancer and illustrated that targeting claudin-4-expressing tumors with CPE resulted in extensive tumor cell necrosis and a substantial decrease in tumor growth (Michl 2001). The gene discussed is CLDN4; the disease is neoplasm.